Whitehawk Therapeutics (NASDAQ:WHWK) Stock Rating Lowered by Wall Street Zen

Whitehawk Therapeutics (NASDAQ:WHWK) was downgraded by investment analysts at Wall Street Zen to a “strong sell” rating in a report released on Saturday.

WHWK has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Whitehawk Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded Whitehawk Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 7th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Whitehawk Therapeutics Stock Performance

Shares of WHWK opened at $2.40 on Friday. The stock has a market cap of $113.11 million, a price-to-earnings ratio of -40.00 and a beta of 0.58. The company’s fifty day moving average is $2.04. Whitehawk Therapeutics has a 1-year low of $1.39 and a 1-year high of $3.81.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its earnings results on Thursday, August 7th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($1.25). Whitehawk Therapeutics had a net margin of 99.42% and a negative return on equity of 75.99%.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.